Dipeptidyl Peptidase IV (DP IV, CD26) and Aminopeptidase N (APN, CD13) as Regulators of T Cell Function and Targets of Immunotherapy in CNS Inflammation

  • Aliza Biton
  • Ute Bank
  • Michael Täger
  • Siegfried Ansorge
  • Dirk Reinhold
  • Uwe Lendeckel
  • Stefan Brocke
Part of the Advances in Experimental Medicine and Biology book series (volume 575)

5. Conclusions

In conclusion, these findings from in vitro and in vivo studies demonstrate that DP IV activity associated with CD26 plays an important role in the activation of autoreactive T cells. Moreover, inhibition of both DP IV/CD26 and APN/CD13 activity in vitro and in vivo provides a new approach to modulate T cell functions and tissue-specific autoimmunity in the CNS. These results may have important implications for the treatment of human diseases with a putative autoimmune pathogenesis. At present, major research efforts are directed at the investigation of DP IV/CD26 and APN/CD13 as potentially powerful and safe pharmacological targets. Our preliminary data raise the possibility that simultaneous inhibition of DP IV/CD26 and APN/CD13 may be advantageous over targeting a single ectopeptidase, and support the development of inhibitors with dual specificities for both ectopeptidases.


Multiple Sclerosis Myelin Basic Protein Dipeptidyl Peptidase Magnetic Resonance Imaging Disease Magnetic Resonance Imaging Disease Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ansorge S, Bühling F, Kähne T, Lendeckel U, Reinhold D, Täger M, Wrenger S, 1997, CD26/dipeptidyl peptidase IV in lymphocyte growth regulation. Adv Exp Med Biol. 421: 127–40.PubMedGoogle Scholar
  2. Arndt M, Lendeckel U, Spiess A, Faust J, Neubert K, Reinhold D, Ansorge S, 2000, Dipeptidyl peptidase IV (DP IV/CD26) mRNA expression in PWM-stimulated T-cells is suppressed by specific DP IV inhibition, an effect mediated by TGF-beta(1). Biochem Biophys Res Commun. 274: 410–414.CrossRefPubMedGoogle Scholar
  3. Bomprezzi R, Ringner M, Kim S, Bittner ML, Khan J, Chen Y, Elkahloun A, Yu A, Bielekova B, Meltzer PS, Martin R, McFarland HF, Trent JM, 2003, Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet. 12: 2191–2199.CrossRefPubMedGoogle Scholar
  4. Cavani A, Nasorri F, Prezzi C, Sebastiani S, Albanesi C, Girolomoni G, 2000, Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol. 114: 295–302.CrossRefPubMedGoogle Scholar
  5. Constantinescu CS, Kamoun M, Dotti M, Farber RE, Galetta SL, Rostami A, 1995, A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. J Neurol Sci. 130: 178–182.CrossRefPubMedGoogle Scholar
  6. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C, 1990, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 144: 4092–4100.PubMedGoogle Scholar
  7. De Meester I, Korom S, Van Damme J, Scharpe S, 1999, CD26, let it cut or cut it down. Immunol Today. 20: 367–375.CrossRefPubMedGoogle Scholar
  8. De Meester I, Lambeir AM, Proost P, Scharpe S, 2003, Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol 524: 3–17.PubMedGoogle Scholar
  9. Fleischer B, 1994, CD26: a surface protease involved in T-cell activation. Immunol Today. 15: 180–184.CrossRefPubMedGoogle Scholar
  10. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL, 1985, In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 312: 1405–1411.PubMedCrossRefGoogle Scholar
  11. Hanski C, Huhle T, Reutter W, 1985, Involvement of plasma membrane dipeptidyl peptidase IV in fibronectin-mediated adhesion of cells on collagen. Biol Chem Hoppe Seyler. 366: 1169–1176.PubMedGoogle Scholar
  12. Hopsu-Havu VK, Glenner GG, 1966, A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie. 7: 197–201.CrossRefPubMedGoogle Scholar
  13. Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang NH, Schlossman SF, Morimoto C, 2001, CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA. 98: 12138–12143.CrossRefPubMedGoogle Scholar
  14. Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, Schlossman SF, Morimoto C, 1999, CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol. 11: 417–426.CrossRefPubMedGoogle Scholar
  15. James MJ, Belaramani L, Prodromidou K, Datta A, Nourshargh S, Lombardi G, Dyson J, Scott D, Simpson E, Cardozo L, Warrens A, Szydlo RM, Lechler RI, Marelli-Berg FM, 2003, Anergic T cells exert antigen-independent inhibition of cell-cell interactions via chemokine metabolism. Blood. 102: 2173–2179.CrossRefPubMedGoogle Scholar
  16. Jensen J, Langkilde AR, Fenst C, Nicolaisen MS, Roed HG, Christiansen M, Sellebjerg F, 2004, CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol. 149: 202–209.CrossRefPubMedGoogle Scholar
  17. Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D, 1999, Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 4: 3–15.PubMedGoogle Scholar
  18. Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C, 1993, Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science. 261: 466–469.CrossRefPubMedGoogle Scholar
  19. Kameoka J, Sato T, Torimoto Y, Sugita K, Soiffer RJ, Schlossman SF, Ritz J, Morimoto C, 1995, Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 85: 1132–1137.PubMedGoogle Scholar
  20. Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL, 2000, Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 57: 1183–1189.CrossRefPubMedGoogle Scholar
  21. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpe S, Kupiec-Weglinski JW, 1997, Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 63: 1495–1500.CrossRefPubMedGoogle Scholar
  22. Korom S, De Meester I, Onodera K, Stadlbauer TH, Borloo M, Lambeir AM, Kupiec-Weglinski JW, 1997, The effects of CD26/DPP IV-targeted therapy on acute allograft rejection. Transplant Proc. 29: 1274–1275.CrossRefPubMedGoogle Scholar
  23. Korom S, De Meester I, Coito AJ, Graser E, Pratschke J, Konig S, Grimm H, Volk HD, Scharpe S, Kupiec-Weglinski JW, 1999, CD26/DPP IV-mediated modulation of acute rejection. Transplant Proc. 31: 873.CrossRefPubMedGoogle Scholar
  24. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J, De Meester I, 2001, Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 276: 29839–29845.CrossRefPubMedGoogle Scholar
  25. Lambeir AM, Durinx C, Scharpe S, De Meester I, 2003, Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 40: 209–294.PubMedGoogle Scholar
  26. Lendeckel U, Arndt M, Bukowska A, Tadje J, Wolke C, Kähne T, Neubert K, Faust J, Ittenson A, Ansorge S, Reinhold D, 2003, Synergistic action of DPIV and APN in the regulation of T cell function. Adv Exp Med Biol. 524: 123–131.PubMedGoogle Scholar
  27. Lojda Z, 1977, Studies on glycyl-proline naphthylamidase. I. Lymphocytes. Histochemistry. 54: 299–309.CrossRefPubMedGoogle Scholar
  28. Lorey S, Stöckel-Maschek A, Faust J, Brandt W, Stiebitz B, Gorrell MD, Kähne T, Mrestani-Klaus C, Wrenger S, Reinhold D, Ansorge S, Neubert K, 2003, Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Eur J Biochem. 270: 2147–2156.CrossRefPubMedGoogle Scholar
  29. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, Detheux M, Parmentier M, Durinx C, Lambeir AM, Neyts J, Liekens S, Maudgal PC, Billiau A, Van Damme J, 2001, Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood. 98: 3554–3561.CrossRefPubMedGoogle Scholar
  30. Reinhold D, Bank U, Bühling F, Lendeckel U, Ulmer AJ, Flad HD, Ansorge S, 1994, Transforming growth factor-beta 1 (TGF-beta 1) inhibits DNA synthesis of PWM-stimulated PBMC via suppression of IL-2 and IL-6 production. Cytokine. 6: 382–388.CrossRefPubMedGoogle Scholar
  31. Reinhold D, Bank U, Bühling F, Lendeckel U, Ansorge S, 1995, Transforming growth factor beta 1 inhibits interleukin-10 mRNA expression and production in pokeweed mitogen-stimulated peripheral blood mononuclear cells and T cells. J Interferon Cytokine Res. 15: 685–690.PubMedCrossRefGoogle Scholar
  32. Reinhold D, Bank U, Buhling F, Lendeckel U, Faust J, Neubert K, Ansorge S, 1997, Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology. 91: 354–360.CrossRefPubMedGoogle Scholar
  33. Reinhold D, Bank U, Bühling F, Tager M, Born I, Faust J, Neubert K, Ansorge S, 1997, Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett. 58: 29–35.CrossRefPubMedGoogle Scholar
  34. Reinhold D, Hemmer B, Gran B, Born I, Faust J, Neubert K, McFarland HF, Martin R, Ansorge S, 1998, Inhibitors of dipeptidyl peptidase IV/CD26 suppress activation of human MBP-specific CD4+ T cell clones. J Neuroimmunol. 87: 203–209.CrossRefPubMedGoogle Scholar
  35. Rogge L, Bianchi E, Biffi M, Bono E, Chang SY, Alexander H, Santini C, Ferrari G, Sinigaglia L, Seiler M, Neeb M, Mous J, Sinigaglia F, Certa U, 2000, Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet. 25: 96–101.CrossRefPubMedGoogle Scholar
  36. Schön E, Mansfeld HW, Demuth HU, Barth A, Ansorge S, 1985, The dipeptidyl peptidase IV, a membrane enzyme involved in the proliferation of T lymphocytes. Biomed Biochim Acta. 44: K9–15.PubMedGoogle Scholar
  37. Sedo A, Malik R, 2001, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochim Biophys Acta. 1550: 107–116.PubMedGoogle Scholar
  38. Sellebjerg F, Jensen J, Madsen HO, Svejgaard A, 2000, HLA DRB1*1501 and intrathecal inflammation in multiple sclerosis. Tissue Antigens. 55: 312–318.CrossRefPubMedGoogle Scholar
  39. Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P, 2000, CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 102: 98–106.CrossRefPubMedGoogle Scholar
  40. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S, 2000, Dipeptidyl peptidase IV in inflammatory CNS disease. Adv Exp Med Biol. 477: 145–153.PubMedGoogle Scholar
  41. Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S, 2001, Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo. J Immunol. 166: 2041–2048.PubMedGoogle Scholar
  42. Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T, 1997, Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol. 19: 15–24.CrossRefPubMedGoogle Scholar
  43. Tanaka S, Murakami T, Nonaka N, Ohnuki T, Yamada M, Sugita T, 1998, Anti-arthritic effects of the novel dipeptidyl peptidase IV inhibitors TMC-2A and TSL-225. Immunopharmacology. 40: 21–26.CrossRefPubMedGoogle Scholar
  44. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C, 1991, Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 147: 2514–2517.PubMedGoogle Scholar
  45. Vivier I, Marguet D, Naquet P, Bonicel J, Black D, Li CX, Bernard AM, Gorvel JP, Pierres M, 1991, Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol. 147: 447–454.PubMedGoogle Scholar
  46. Wrenger S, Reinhold D, Hoffmann T, Kraft M, Frank R, Faust J, Neubert K, Ansorge S, 1996, The N-terminal XX-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells. FEBS Lett. 383: 145–149.CrossRefPubMedGoogle Scholar
  47. Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S, Reinhold D, 1997, The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J Biol Chem. 272: 30283–30288.CrossRefPubMedGoogle Scholar
  48. Wrenger S, Kähne T, Bohuon C, Weglohner W, Ansorge S, Reinhold D, 2000, Amino-terminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett. 466: 155–159.CrossRefPubMedGoogle Scholar
  49. Wrenger S, Reinhold D, Faust J, Mrestani-Klaus C, Brandt W, Fengler A, Neubert K, Ansorge S, 2000, Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth. Adv Exp Med Biol. 477: 161–165.PubMedCrossRefGoogle Scholar
  50. Wrenger S, Faust J, Mrestani-Klaus C, Fengler A, Stockel-Maschek A, Lorey S, Kahne T, Brandt W, Neubert K, Ansorge S, Reinhold D, 2000, Down-regulation of T cell activation following inhibition of dipeptidyl peptidase IV/CD26 by the N-terminal part of the thromboxane A2 receptor. J Biol Chem. 275: 22180–22186.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Aliza Biton
    • 1
  • Ute Bank
    • 2
  • Michael Täger
    • 2
  • Siegfried Ansorge
    • 2
  • Dirk Reinhold
    • 3
  • Uwe Lendeckel
    • 4
  • Stefan Brocke
    • 1
    • 5
  1. 1.Department of Pathology, Faculty of MedicineHebrew University-Hadassah Medical SchoolJerusalemIsrael
  2. 2.IMTMMagdeburgGermany
  3. 3.Institute of ImmunologyOtto-von-Guericke University MagdeburgMagdeburgGermany
  4. 4.Institute of Experimental Internal MedicineOtto-von-Guericke University MagdeburgMagdeburgGermany
  5. 5.Department of PharmacologyUniversity of Connecticut Health CenterFarmingtonUSA

Personalised recommendations